Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

The role of glutamatergic modulation in the mechanism of action of ketamine, a prototype rapid-acting antidepressant drug.

Pałucha-Poniewiera A.

Pharmacol Rep. 2018 Feb 9;70(5):837-846. doi: 10.1016/j.pharep.2018.02.011. [Epub ahead of print] Review.

PMID:
30086517
2.

The involvement of monoaminergic neurotransmission in the antidepressant-like action of scopolamine in the tail suspension test.

Pałucha-Poniewiera A, Podkowa K, Lenda T, Pilc A.

Prog Neuropsychopharmacol Biol Psychiatry. 2017 Oct 3;79(Pt B):155-161. doi: 10.1016/j.pnpbp.2017.06.022. Epub 2017 Jun 21.

PMID:
28647535
3.

Antidepressant-like effects of scopolamine in mice are enhanced by the group II mGlu receptor antagonist LY341495.

Podkowa K, Podkowa A, Sałat K, Lenda T, Pilc A, Pałucha-Poniewiera A.

Neuropharmacology. 2016 Dec;111:169-179. doi: 10.1016/j.neuropharm.2016.08.031. Epub 2016 Aug 25.

PMID:
27569995
4.

Glutamate-Based Drug Discovery for Novel Antidepressants.

Pałucha-Poniewiera A, Pilc A.

Expert Opin Drug Discov. 2016 Sep;11(9):873-83. doi: 10.1080/17460441.2016.1213234. Epub 2016 Aug 2. Review.

PMID:
27409299
5.

Group II mGlu receptor antagonist LY341495 enhances the antidepressant-like effects of ketamine in the forced swim test in rats.

Podkowa K, Pochwat B, Brański P, Pilc A, Pałucha-Poniewiera A.

Psychopharmacology (Berl). 2016 Aug;233(15-16):2901-14. doi: 10.1007/s00213-016-4325-7. Epub 2016 Jun 11.

6.

Activation of mTOR dependent signaling pathway is a necessary mechanism of antidepressant-like activity of zinc.

Szewczyk B, Pochwat B, Rafało A, Palucha-Poniewiera A, Domin H, Nowak G.

Neuropharmacology. 2015 Dec;99:517-26. doi: 10.1016/j.neuropharm.2015.08.026. Epub 2015 Aug 19.

PMID:
26297535
7.

A novel mGlu4 selective agonist LSP4-2022 increases behavioral despair in mouse models of antidepressant action.

Podkowa K, Rzeźniczek S, Marciniak M, Acher F, Pilc A, Pałucha-Poniewiera A.

Neuropharmacology. 2015 Oct;97:338-45. doi: 10.1016/j.neuropharm.2015.05.039. Epub 2015 Jun 12.

PMID:
26074092
8.

NMDA antagonists under investigation for the treatment of major depressive disorder.

Pochwat B, Pałucha-Poniewiera A, Szewczyk B, Pilc A, Nowak G.

Expert Opin Investig Drugs. 2014 Sep;23(9):1181-92. doi: 10.1517/13543784.2014.918951. Epub 2014 May 12. Review. Erratum in: Expert Opin Investig Drugs. 2014 Oct;23(10):1457.

PMID:
24818801
9.

Prolonged administration of antidepressant drugs leads to increased binding of [(3)H]MPEP to mGlu5 receptors.

Nowak G, Pomierny-Chamioło L, Siwek A, Niedzielska E, Pomierny B, Pałucha-Poniewiera A, Pilc A.

Neuropharmacology. 2014 Sep;84:46-51. doi: 10.1016/j.neuropharm.2014.04.016. Epub 2014 May 4.

PMID:
24796254
10.

Activation of the mTOR signaling pathway in the antidepressant-like activity of the mGlu5 antagonist MTEP and the mGlu7 agonist AMN082 in the FST in rats.

Pałucha-Poniewiera A, Szewczyk B, Pilc A.

Neuropharmacology. 2014 Jul;82:59-68. doi: 10.1016/j.neuropharm.2014.03.001. Epub 2014 Mar 12.

PMID:
24631968
11.

Is the mGlu5 receptor a possible target for new antidepressant drugs?

Pałucha-Poniewiera A, Wierońska JM, Brański P, Burnat G, Chruścicka B, Pilc A.

Pharmacol Rep. 2013;65(6):1506-11. Review.

12.

The antidepressant-like action of mGlu5 receptor antagonist, MTEP, in the tail suspension test in mice is serotonin dependent.

Pałucha-Poniewiera A, Brański P, Wierońska JM, Stachowicz K, Sławińska A, Pilc A.

Psychopharmacology (Berl). 2014 Jan;231(1):97-107.

PMID:
23958941
13.

A selective mGlu7 receptor antagonist MMPIP reversed antidepressant-like effects of AMN082 in rats.

Pałucha-Poniewiera A, Pilc A.

Behav Brain Res. 2013 Feb 1;238:109-12. doi: 10.1016/j.bbr.2012.10.004. Epub 2012 Oct 17.

PMID:
23085340
14.

Involvement of mGlu5 and NMDA receptors in the antidepressant-like effect of acamprosate in the tail suspension test.

Pałucha-Poniewiera A, Pilc A.

Prog Neuropsychopharmacol Biol Psychiatry. 2012 Oct 1;39(1):102-6. doi: 10.1016/j.pnpbp.2012.05.015. Epub 2012 May 29.

PMID:
22651960
15.

Anxiolytic- but not antidepressant-like activity of Lu AF21934, a novel, selective positive allosteric modulator of the mGlu₄ receptor.

Sławińska A, Wierońska JM, Stachowicz K, Pałucha-Poniewiera A, Uberti MA, Bacolod MA, Doller D, Pilc A.

Neuropharmacology. 2013 Mar;66:225-35. doi: 10.1016/j.neuropharm.2012.05.001. Epub 2012 May 23.

PMID:
22634361
16.

Investigational NMDA receptor modulators for depression.

Szewczyk B, Pałucha-Poniewiera A, Poleszak E, Pilc A, Nowak G.

Expert Opin Investig Drugs. 2012 Jan;21(1):91-102. doi: 10.1517/13543784.2012.638916. Epub 2011 Nov 21. Review.

PMID:
22097925
17.

On the mechanism of anti-hyperthermic effects of LY379268 and LY487379, group II mGlu receptors activators, in the stress-induced hyperthermia in singly housed mice.

Wierońska JM, Stachowicz K, Brański P, Pałucha-Poniewiera A, Pilc A.

Neuropharmacology. 2012 Jan;62(1):322-31. doi: 10.1016/j.neuropharm.2011.07.042. Epub 2011 Aug 10.

PMID:
21855555
18.

Metabotropic glutamate receptor 4 novel agonist LSP1-2111 with anxiolytic, but not antidepressant-like activity, mediated by serotonergic and GABAergic systems.

Wierońska JM, Stachowicz K, Pałucha-Poniewiera A, Acher F, Brański P, Pilc A.

Neuropharmacology. 2010 Dec;59(7-8):627-34. doi: 10.1016/j.neuropharm.2010.08.008. Epub 2010 Aug 14.

PMID:
20713068
19.

On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039.

Pałucha-Poniewiera A, Wierońska JM, Brański P, Stachowicz K, Chaki S, Pilc A.

Psychopharmacology (Berl). 2010 Dec;212(4):523-35. doi: 10.1007/s00213-010-1978-5. Epub 2010 Aug 12.

20.

The antidepressant-like action of metabotropic glutamate 7 receptor agonist N,N'-bis(diphenylmethyl)-1,2-ethanediamine (AMN082) is serotonin-dependent.

Pałucha-Poniewiera A, Brański P, Lenda T, Pilc A.

J Pharmacol Exp Ther. 2010 Sep 1;334(3):1066-74. doi: 10.1124/jpet.110.169730. Epub 2010 Jun 18.

21.

Group III mGlu receptor agonist, ACPT-I, attenuates morphine-withdrawal symptoms after peripheral administration in mice.

Pałucha-Poniewiera A, Novák K, Pilc A.

Prog Neuropsychopharmacol Biol Psychiatry. 2009 Nov 13;33(8):1454-7. doi: 10.1016/j.pnpbp.2009.07.029. Epub 2009 Aug 4.

PMID:
19660510
22.

The group III mGlu receptor agonist ACPT-I exerts anxiolytic-like but not antidepressant-like effects, mediated by the serotonergic and GABA-ergic systems.

Stachowicz K, Kłodzińska A, Palucha-Poniewiera A, Schann S, Neuville P, Pilc A.

Neuropharmacology. 2009 Sep;57(3):227-34. doi: 10.1016/j.neuropharm.2009.06.005. Epub 2009 Jun 17.

PMID:
19539634
23.

Peripheral administration of group III mGlu receptor agonist ACPT-I exerts potential antipsychotic effects in rodents.

Pałucha-Poniewiera A, Kłodzińska A, Stachowicz K, Tokarski K, Hess G, Schann S, Frauli M, Neuville P, Pilc A.

Neuropharmacology. 2008 Sep;55(4):517-24. doi: 10.1016/j.neuropharm.2008.06.033. Epub 2008 Jun 27.

PMID:
18619473

Supplemental Content

Loading ...
Support Center